查詢結果分析
相關文獻
- Fusidic Acid眼藥膏治療新生兒Methicillin抗藥性金黃色葡萄球菌結膜炎之評估
- A Review of Ocular Emergencies in a Taiwanese Medical Center
- 紅眼病之中醫診治
- 某教學醫院燒傷加護病房Methicillin抗藥性金黃色葡萄球菌感染之調查研究
- Longitudinal Analysis of Methicillin Resistant Staphylococcus Aureus Isolates at a Teaching Hospital in Taiwan
- 巨大乳頭狀結膜炎
- 急性角結膜炎微生物培養之研究
- 正常眼及過敏性結膜炎之血清及淚水IgE值
- 慢性結膜炎病人的Schirmer氏試驗與淚液半月面高度之比較
- 急性角結膜炎微生物培養之研究
頁籤選單縮合
題 名 | Fusidic Acid眼藥膏治療新生兒Methicillin抗藥性金黃色葡萄球菌結膜炎之評估=Fusidic Acid Eyeointment in Treatment of Nosocomial Neonatal Methicillin-Resistant Staphylococcus Aureus Conjunctivitis |
---|---|
作 者 | 邱南昌; 姜秀子; 莊意芬; 黃富源; | 書刊名 | 院內感染控制雜誌 |
卷 期 | 9:1 1999.02[民88.02] |
頁 次 | 頁1-8 |
分類號 | 418.2323 |
關鍵詞 | Methicillin抗藥性金黃色葡萄球菌; 結膜炎; Fusidic acid; Methicillin-resistant staphylococcus aureus; Conjunctivitis; |
語 文 | 中文(Chinese) |
中文摘要 | 本研究乃評估fusidic acid眼藥膏應用於新生兒methicillin抗藥性金黃色葡萄球菌(methicillin-resistant Staphylococcus aureus, MRSA)結膜炎患者之治療效果。研究對象為1997年一月至十二月在本院出生或住院之新生兒眼部膿樣分泌物經細菌培養證實為MRSA者。病童皆予以隔離,並做(1)鼻腔、(2)腋下及腹股溝皮膚皺褶處、(3)臍部和(4)保溫箱壁之細菌培養。Fusidic acid眼藥膏為一天點兩次,治療三天後再做眼部細菌培養,若未再分離出細菌則治療七天後停藥;若仍有MRSA者繼續fusidic acid眼藥膏治療,每隔七天做一次眼部細菌培養,直到MRSA消失或是症狀惡化而更改為其他藥物治療,或是出院而眼部分泌物消失。其他部位長出MRSA者亦給予處理。有26位新生兒之眼部培養出MRSA。分離出之MRSA做fusidic acid敏感試驗,敏感率為96.3%。17位病童在住院期間成功的自結膜處消除了MRSA,成功率為65.4%。21位病童(80.8%)自鼻腔、13位病童(50.5%)自皮膚皺褶處、11位病童(42.3%)自臍部、4位病童(15.4%)自保溫箱壁分離出MRSA。成功組由其他部位分離出MRSA的比例較失敗組低。MRSA雖對Fusidic acid具高敏感性,但若病人身上其他部位或密切接觸之環境同時有MRSA存在,則可能導致院內結膜感染之治療失敗。 |
英文摘要 | Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most common and troublesome pathogens in neonatal care units. MRSA is resistant to many topical antibiotic preparations for ophthalmic usage. Fusidic acid interferes with the translocation of mRNA to ribosomes and can be employed to treat Staphylococcus aureus infections. This study was to investigate the efficiency of fusidic acid eye-ointment in treating neonates with nosocomial MRSA conjunctivitis. From January to December 1997, hospitalized neonates with MRSA conjunctivitis were included into this study. Swabs from nasal cavities, axillary and inguinal skin folds, umbilicus, and incubator wall were sent for culture. Fusidic acid eye-ointment was applied, then ophthalmic and other site cultures repeated three days later. When MRSA was isolated again, these cultures were repeated seven days after the topical application and the therapy continued, otherwise discontinued. When other pathogens were isolated from the eye discharge other appropriate topical ophthalmic antibiotics were applied. Fusidic acid eye-ointment were given till no MRSA was isolated from the eye dischagrge. Twenty-six neonates had MRSA isolated from eye discharges. Total of 112 specimens yielded MRSA including 44 from the eye discharge. In vitro susceptibility of fusidic acid for MRSA was 96.3% (103/107). MRSA was eradicated from eyes in 17 patients (65.4%). Twenty-one patients (80.8%) also had MRSA isolated from nose, 13 (50.0%) from skin folds, 11 (42.3%) from umbilicus, and 4 (15.4%) from incubator. Patients in whom conjunctival MRSA was succelssfully eradicated had lower concomitant extra-ophthalmic MRSA colonization than those who failed to have the MRSA eradicated, i.e. in nose (70.6% vs 100.0%), skin folds (41.2% vs 66.7%), umbilicus (29.4% vs 66.7%), and incubator (11.8% vs 22.2%). Fusidic acid is effective against MRSA in vitro. However, fusidic acid eye-ointment may not eradicate ophthalmic MRSA. Extra-ophthlmic MRSA colonization or environmental contamination plays an important role for the failure of eradication. |
本系統中英文摘要資訊取自各篇刊載內容。